GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Pretax Margin %

Outlook Therapeutics (FRA:41O) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Outlook Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was €-105.14 Mil. Outlook Therapeutics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Outlook Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Outlook Therapeutics's Pretax Margin % or its related term are showing as below:


FRA:41O's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.03
* Ranked among companies with meaningful Pretax Margin % only.

Outlook Therapeutics Pretax Margin % Historical Data

The historical data trend for Outlook Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Pretax Margin % Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -465.66 - - - -

Outlook Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Outlook Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Outlook Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Pretax Margin % falls into.



Outlook Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Outlook Therapeutics's Pretax Margin for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-55.264/0
= %

Outlook Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-105.143/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (FRA:41O) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Outlook Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (FRA:41O) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines